Table 3. Inhibition of ABT on T20-resistant HIV-1 variantsa.
| HIV-1NL4-3 b | T20 | C34 | ABT | AZT | ||||
| IC50 (nM) | Fold changec | IC50 (nM) | Fold change | IC50 (nM) | Fold change | IC50 (nM) | Fold change | |
| WT | 62.5±11.9 | 1.0 (8.3) | 2.0±0.6 | 1.0 (1.8) | 1.9±0.4 | 1.0 (0.6) | 106.7±23.2 | 1.0 (1.8) |
| D36G | 7.5±1.3 | 0.1 (1.0) | 1.1±0.1 | 0.6 (1.0) | 3.3±0.8 | 1.7 (1.0) | 59.4±5.9 | 0.6 (1.0) |
| I37T | 300.2±55.1 | 4.8 (40.0) | 20.5±1.7 | 10.3 (18.6) | 7.6±1.0 | 4.0 (2.3) | 93.5±13.5 | 0.9 (1.6) |
| V38A | 1261.0±182.3 | 20.2 (168.1) | 47.2±10.8 | 23.6 (42.9) | 8.5±1.2 | 4.5 (2.6) | 42.3±9.0 | 0.4 (0.7) |
| V38M | 645.6±57.7 | 10.3 (86.1) | 16.5±4.2 | 8.3 (15.0) | 8.7±1.4 | 4.5 (2.6) | 47.8±3.7 | 0.5 (0.8) |
| Q40H | 731.4±35.2 | 11.7 (97.5) | 39.9±5.3 | 20.0 (36.3) | 9.7±2.0 | 6.5 (2.9) | 33.2±7.2 | 0.3 (0.6) |
| N43K | 262.3±44.4 | 4.2 (35.0) | 26.3±3.5 | 13.2 (23.9) | 5.9±0.9 | 3.1 (1.8) | 153.3±7.4 | 1.4 (2.6) |
| D36S/V38M | 322.5±60.3 | 5.2 (43.0) | 11.3±1.6 | 5.7 (10.3) | 10.3±0.9 | 5.4 (3.1) | 40.3±8.6 | 0.4 (0.7) |
| I37T/N43K | >3,000.0 | >48.0 (>400.0) | 261.8±47.4 | 131.9 (238.0) | 32.4±5.9 | 17.1 (9.8) | 138.9±14.9 | 1.3 (2.3) |
| V38A/N42T | >3,000.0 | >48.0 (>400.0) | 444.3±133 | 222.2 (403.9) | 7.8±1.5 | 4.1 (2.4) | 38.1±3.7 | 0.4 (0.6) |
| L33S | >750.0 | NA | ND | NA | 2.7±0.3 | NA | ND | NA |
| I37V/V38T | >750.0 | NA | ND | NA | 4.1±0.8 | NA | ND | NA |
a
The data were derived from the results of three independent experiments and are expressed as means ± standard deviations.
b
HIV-1NL4-3-based pseudoviruses were constructed and used in the single-cycle infection assays except that L33S and I37V/V38T are infectious molecular clones of HIV-1NL4-3.
c
Both wild-type (WT) and D36G were used as reference viruses to calculate the resistance fold-changes.Shown in parentheses are based on the D36G as a reference.